PubRank

H T Hatoum

Author PubWeight™ 14.89‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: tests of data quality, scaling assumptions and score reliability. Med Care 1999 1.78
2 The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: relative validity of scales in relation to clinical measures of arthritis severity. Med Care 1999 1.75
3 Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996 1.56
4 Toxicity of MDA (3,4-methylenedioxyamphetamine) considered for relevance to hazards of MDMA (Ecstasy) abuse. Alcohol Drug Res 1987 1.17
5 The SF-36 Arthritis-Specific Health Index (ASHI): I. Development and cross-validation of scoring algorithms. Med Care 1999 1.14
6 Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 1996 1.02
7 The SF-36 Arthritis-Specific Health Index (ASHI): II. Tests of validity in four clinical trials. Med Care 1999 1.01
8 Safety and efficacy of retreatment with a bioengineered hyaluronate for painful osteoarthritis of the knee: results of the open-label Extension Study of the FLEXX Trial. Osteoarthritis Cartilage 2011 0.94
9 Prevalence and cost of hospitalization for gastrointestinal complications related to peptic ulcers with bleeding or perforation: comparison of two national databases. Am J Manag Care 1998 0.87
10 An eleven-year review of the pharmacy literature: documentation of the value and acceptance of clinical pharmacy. Drug Intell Clin Pharm 1986 0.86
11 Acute toxicity and gross behavioral effects of amphetamine, four methoxyamphetamines, and mescaline in rodents, dogs, and monkeys. Toxicol Appl Pharmacol 1978 0.81
12 Multilevel model to assess appropriateness of pediatric serum drug concentrations. Am J Dis Child 1991 0.78
13 Interactions of catecholaminergic receptor blockers with lethal doses of amphetamine or substituted amphetamines in mice. Res Commun Chem Pathol Pharmacol 1978 0.76
14 How much faith can we have in pharmacoeconomic analyses? Pharmacoeconomics 1994 0.75
15 Contribution of clinical pharmacists to cefazolin utilization. Hosp Formul 1987 0.75
16 The use of pharmacy personnel to positively impact hospital finances. Hosp Formul 1989 0.75
17 Long-term survival strategy for the pharmacy profession. Drug Intell Clin Pharm 1985 0.75
18 Updating the costs of preparing small-volume injections. Am J Hosp Pharm 1989 0.75
19 Managing patient-oriented pharmacy services--challenges and solutions. Curr Concepts Hosp Pharm Manage 1988 0.75
20 Inconsistencies in the drug use process. DICP 1990 0.75
21 Triphasic dose-lethality relationships for amphetamine and certain ring-substituted amphetamines in isolated or aggregated mice. Res Commun Chem Pathol Pharmacol 1977 0.75
22 Cost justification of clinical pharmacy services on a general surgery team: focus on diagnosis-related group cases. Drug Intell Clin Pharm 1988 0.75
23 The need for and methods of cost-justifying hospital pharmacy services. J Pharm Mark Manage 1987 0.75
24 Comparison of stimulants and hallucinogens on shuttle avoidance in rats. Gen Pharmacol 1987 0.75
25 A comparative profile of clinical pharmacy activities for pharmacotherapists and residents in a university hospital. Pharm Pract Manag Q 1996 0.75
26 Microcosting method for small-volume injectables. Am J Hosp Pharm 1986 0.75
27 Program to improve nurses' knowledge of pediatric emergency medications. Am J Hosp Pharm 1991 0.75